Alendronate sodium
| Status | Commercial |
| Development phase | |
| Therapeutic cat. | Musculo-skeletal |
| Polymorphic form | Trihydrate |
| CAS No. | 121268-17-5 |
| Reference Product | |
| Injectable Form | Injectable |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Alendronate is used to treat osteoporosis caused by menopause, steroid use, or gonadal failure. alendronate is for use when you have a high risk of bone fracture due to osteoporosis. Alendronate is also used to treat Paget's disease of bone. Alendronate may also be used for purposes not listed in this medication guide.
Polpharma API
- No risk of nitrozamines presence
- Extensive experience with commercial manufacturing
- In house production of the whole product family (Risedronate, Zoledronate, Ibandronate)
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
